Alumis Inc. Common Stock (ALMS) is a Biotechnology company in the Healthcare sector, currently trading at $22.89. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is ALMS = $38 (+67.9% upside).
Valuation: ALMS trades at a trailing Price-to-Earnings (P/E) of -9.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 4.84.
Financials: revenue is $24M, +0%/yr average growth. Net income is $243M (loss), growing at -37%/yr. Net profit margin is -1011.7% (negative). Gross margin is 85.5% (+0 pp trend).
Balance sheet: total debt is $37M against $301M equity (Debt-to-Equity (D/E) ratio 0.12, conservative). Current ratio is 4.34 (strong liquidity). Debt-to-assets is 9%. Total assets: $412M.
Analyst outlook: 8 / 8 analysts rate ALMS as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 48/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 58/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
